Onderneming Chimeric Therapeutics Limited
Aandelen
CHM
AU0000121576
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,019 AUD | +5,56% | -13,64% | -45,71% |
22/05 | Chimeric Therapeutics' eerste humane CHM CDH17 studie opent voor inschrijving; aandelen stijgen 4%. | MT |
02/05 | Chimeric Therapeutics benoemt COO; Aandelen stijgen 4% | MT |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 12-07-23 |
Chief Tech/Sci/R&D Officer | - | 05-07-22 | |
Li Ren
CTO | Chief Tech/Sci/R&D Officer | - | 25-06-21 |
Jason B. Litten
CTO | Chief Tech/Sci/R&D Officer | 50 | 25-07-22 |
Elizabeth Chang
PRN | Corporate Officer/Principal | - | - |
Eliot Bourk
PRN | Corporate Officer/Principal | - | 23-02-21 |
Nathan Jong
SEC | Corporate Secretary | - | - |
Alison Gartner
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 60 | 03-02-22 | |
Corporate Officer/Principal | 63 | 08-08-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 28-08-20 |
Paul Hopper
FOU | Founder | 68 | 02-02-20 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 12-07-23 |
Eric Sullivan
BRD | Director/Board Member | - | 30-08-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 725 840 586 | 652 667 576 ( 89,92 %) | 0 | 89,92 % |
Bedrijfsgegevens
Chimeric Therapeutics Ltd. (Australia)
62 Lygon Street Level 3
3053, Carlton
+
http://www.chimerictherapeutics.comSector
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-45,71% | 10,31 mln. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,26% | 21,96 mld. | |
-8,07% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |